INSIDER
01Overview02Follow the Money03Daily Brief04Live05Congress06Corporate Insiders07Government Money08Political Influence09Institutions10Washington Network11Follow the Power12Disclosure Clock13AI Investigator14Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

RH CHAIN…
OverviewFollow the MoneyDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
01Overview02Follow the Money03Daily Brief04Live05Congress06Corporate Insiders07Government Money08Political Influence09Institutions10Washington Network11Follow the Power12Disclosure Clock13AI Investigator14Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
OverviewFollow the MoneyDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
Data sources
SEC FORM 43h ago
HOUSE PTR3h ago
SEC 13F3h ago
ROBINHOOD CHAIN3h ago
SEC FORM 4/Grant or awardVerified data

Ellinor Patrick Thomas II reported EDIT

Director · Editas Medicine, Inc. · Editas Medicine, Inc. — Stock Option (right to buy)

Side
A
Value
—
Shares
103.4K
Price
—
Executed
Aug 6, 2026
Disclosed
Aug 7, 2026
Disclosure timeline1 days from execution to publication · legal deadline 2 business days
Aug 6 executedAug 7, 2026 disclosed

EDIT · daily

Yahoo Finance chart API
▲Execution▼Disclosure●Material company filing●Other disclosed buy●Other disclosed sellUnofficial public endpoint; daily OHLCV, split-adjusted. Replace with a licensed feed for production.

Insider Score

Experimental signal
9/ 100 · ROUTINE
Methodology →
  • Transaction type0 / 20

    Grant or award — administrative, little informational value

  • Relative size+1 / 25

No reported dollar value · new position

  • Filing timing0 / 15

    Disclosed 1 business day after execution (deadline: 2)

  • Historical behavior+8 / 15

    First recorded trade by this actor in this security

  • Frequency & clustering0 / 15

    No clustered activity in the dataset

  • Market events0 / 10

    No material company filing within 60 days after the trade

    • The Insider Score measures how far a disclosure deviates from normal filing patterns. A high score is a prompt for research, not evidence of illegal insider trading.

    Other disclosed activity · EDIT

    ScoreActorSecuritySideValueExecutedDisclosedLagSourceEvidence
    9
    OS
    Ory Daniel ScottEVP, Chief Medical Officer
    EDITEditas Medicine, Inc.
    Grant or award
    		A—
    950.0K sh
    		Sep 8, 2026Sep 9, 2026
    traded Sep 8, 2026
    		+1dSEC FORM 4

    Evidence

    11
    PA
    Parison AmySVP, Chief Financial Officer
    EDITEditas Medicine, Inc.
    Open-market sale · 10b5-1 plan
    		SELL$1,376
    453 sh
    		Sep 3, 2026Sep 4, 2026
    traded Sep 3, 2026
    		+1dSEC FORM 4

    Evidence

    11
    ON
    O'Neill Gilmore NeilDirector, CEO
    EDITEditas Medicine, Inc.
    Open-market sale · 10b5-1 plan
    		SELL$16K
    5,124 sh
    		Sep 3, 2026Sep 4, 2026
    traded Sep 3, 2026
    		+1dSEC FORM 4

    Evidence

    11
    BL
    Burkly LindaEVP, CHIEF SCIENTIFIC OFFICER
    EDITEditas Medicine, Inc.
    Open-market sale · 10b5-1 plan
    		SELL$2,153
    709 sh
    		Sep 3, 2026Sep 4, 2026
    traded Sep 3, 2026
    		+1dSEC FORM 4

    Evidence

    15
    BL
    Burkly LindaEVP, CHIEF SCIENTIFIC OFFICER
    EDITEditas Medicine, Inc.
    Open-market sale · 10b5-1 plan
    		SELL$1,535
    713 sh
    		Dec 3, 2025Dec 4, 2025
    traded Dec 3, 2025
    		+1dSEC FORM 4

    Evidence

    15
    ON
    O'Neill Gilmore NeilDirector, CEO
    EDITEditas Medicine, Inc.
    Open-market sale · 10b5-1 plan
    		SELL$12K
    5,603 sh
    		Dec 3, 2025Dec 4, 2025
    traded Dec 3, 2025
    		+1dSEC FORM 4

    Evidence

    15
    PA
    Parison AmySVP, Chief Financial Officer
    EDITEditas Medicine, Inc.
    Open-market sale · 10b5-1 plan
    		SELL$993
    461 sh
    		Dec 3, 2025Dec 4, 2025
    traded Dec 3, 2025
    		+1dSEC FORM 4

    Evidence

    Evidence

    Verified data

    Read directly from the primary public document; every field below is as reported by the filer.

    Source

    Document
    SEC Form 4
    Publisher
    U.S. Securities and Exchange Commission (EDGAR)
    Document ID
    0002137699-26-000004
    Machine-readable
    Structured copy

    Timestamps

    Event (reported)
    Aug 6, 2026
    Published
    Aug 7, 2026
    Ingested by INSIDER
    Nov 5, 02:24 UTC
    Last re-read
    Nov 5, 02:24 UTC

    Extracted facts

    Filer
    Ellinor Patrick Thomas II
    Role
    Director
    Transaction
    Grant or awardAs filed: “A”
    Asset
    Editas Medicine, Inc. — Stock Option (right to buy)
    Ticker
    EDIT
    Shares
    103.4K
    Price per share
    $0
    Execution date (reported)
    Aug 6, 2026
    Owned after transaction
    103.4K shares
    Days from execution to publication
    1

    What this establishes

    Ellinor Patrick Thomas II filed this Form 4 reporting a grant or award of EDIT on Aug 6, 2026. It became public on Aug 7, 2026. The filing establishes the reported transaction and the filer's stated role. It does not establish why the trade was made or what the filer knew.

    Extraction

    Method
    Form 4 XML
    Confidence
    1.00
    Director
    Ellinor Patrick Thomas IIcik:0002137699
    Issuer
    Editas Medicine, Inc.cik:0001650664

    Revision history · 0

    No field has changed since this record was first ingested.

    Company events

    No records

    No material filings recorded for this issuer.